Tags

Type your tag names separated by a space and hit enter

YAZ and the novel progestin drospirenone.

Abstract

Drospirenone is a novel progestin that is structurally related to 17 alpha-spirolactone and has antimineralocorticoid and antiandrogenic activity. A 3-mg dose of drospirenone was first used in combination with ethinyl estradiol (EE) 30 microg in a combination oral contraceptive (COC) that is administered for 21 days, followed by a 7-day hormone-free interval (HFI) (drospirenone/30EE, or Yasmin). The 21/7 regimen is considered to be the standard regimen for COC delivery. A formulation with the metabolic benefit of COCs containing a lower estrogen dose has been developed combining drospirenone 3 mg with EE 20 microg and using a regimen of 24 days of active pills, followed by a 4-day HFI (drospirenone/20EE-24/4), or YAZ (Bayer HealthCare Pharmaceuticals Inc., Wayne, New Jersey). Since drospirenone has a half-life of > 30 hours, its activity extends for a prolonged time into the shortened HFI. This new COC has been shown to provide effective contraception and to have a good safety profile. Two large noninterventional studies have recently evaluated the safety of drospirenone/30EE in 2 areas of special interest: hyperkalemia and thromboembolic events. Use of a drospirenone-containing COC was not associated with an increased risk of either type of disorder in comparison with COCs containing other progestins. Drospirenone/20EE-24/4 provides a low dose of EE in combination with drospirenone in an effective and safe COC that is administered using a regimen with a shortened HFI. Drospirenone/20EE-24/4 is the only COC with 3 indications: contraception and the treatment of premenstrual dysphoric disorder in women who wish to use a COC for birth control, and the treatment of moderate acne in women who are at least 14-years-old, have achieved menarche and wish to use a COC for birth control.

Authors+Show Affiliations

Department of Obstetrics and Gynecology, Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA. mishell@usc.edu

Source

The Journal of reproductive medicine 53:9 Suppl 2008 Sep pg 721-8

MeSH

Acne Vulgaris
Adolescent
Adult
Androstenes
Contraceptives, Oral, Combined
Drug Administration Schedule
Drug Combinations
Ethinyl Estradiol
Female
Humans
Menstrual Cycle
Molecular Structure
Patient Satisfaction
Premenstrual Syndrome

Pub Type(s)

Journal Article

Language

eng

PubMed ID

18980044

Citation

Mishell, Daniel R.. "YAZ and the Novel Progestin Drospirenone." The Journal of Reproductive Medicine, vol. 53, no. 9 Suppl, 2008, pp. 721-8.
Mishell DR. YAZ and the novel progestin drospirenone. J Reprod Med. 2008;53(9 Suppl):721-8.
Mishell, D. R. (2008). YAZ and the novel progestin drospirenone. The Journal of Reproductive Medicine, 53(9 Suppl), pp. 721-8.
Mishell DR. YAZ and the Novel Progestin Drospirenone. J Reprod Med. 2008;53(9 Suppl):721-8. PubMed PMID: 18980044.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - YAZ and the novel progestin drospirenone. A1 - Mishell,Daniel R,Jr PY - 2008/11/5/pubmed PY - 2009/1/27/medline PY - 2008/11/5/entrez SP - 721 EP - 8 JF - The Journal of reproductive medicine JO - J Reprod Med VL - 53 IS - 9 Suppl N2 - Drospirenone is a novel progestin that is structurally related to 17 alpha-spirolactone and has antimineralocorticoid and antiandrogenic activity. A 3-mg dose of drospirenone was first used in combination with ethinyl estradiol (EE) 30 microg in a combination oral contraceptive (COC) that is administered for 21 days, followed by a 7-day hormone-free interval (HFI) (drospirenone/30EE, or Yasmin). The 21/7 regimen is considered to be the standard regimen for COC delivery. A formulation with the metabolic benefit of COCs containing a lower estrogen dose has been developed combining drospirenone 3 mg with EE 20 microg and using a regimen of 24 days of active pills, followed by a 4-day HFI (drospirenone/20EE-24/4), or YAZ (Bayer HealthCare Pharmaceuticals Inc., Wayne, New Jersey). Since drospirenone has a half-life of > 30 hours, its activity extends for a prolonged time into the shortened HFI. This new COC has been shown to provide effective contraception and to have a good safety profile. Two large noninterventional studies have recently evaluated the safety of drospirenone/30EE in 2 areas of special interest: hyperkalemia and thromboembolic events. Use of a drospirenone-containing COC was not associated with an increased risk of either type of disorder in comparison with COCs containing other progestins. Drospirenone/20EE-24/4 provides a low dose of EE in combination with drospirenone in an effective and safe COC that is administered using a regimen with a shortened HFI. Drospirenone/20EE-24/4 is the only COC with 3 indications: contraception and the treatment of premenstrual dysphoric disorder in women who wish to use a COC for birth control, and the treatment of moderate acne in women who are at least 14-years-old, have achieved menarche and wish to use a COC for birth control. SN - 0024-7758 UR - https://www.unboundmedicine.com/medline/citation/18980044/YAZ_and_the_novel_progestin_drospirenone_ DB - PRIME DP - Unbound Medicine ER -